MD - University of Athens School of Health Sciences, Greece
Pediatrics - SUNY Downstate Medical Center, Brooklyn, NY
Infectious Diseases - Children's Hospital of Philadelphia, Philadelphia, PA
Fellow
C, D., & Zhang, D., & Stashko, M., & Vasileiadi, E., & Parker, R., & Minson, KA., & Huey, MG., & Huelse, J., & Hunter, D., & Gilbert, TSK., & Norris-Drouin, J., & Miley, M., & Herring, LE., & Graves, LM., & DeRyckere, D., & Earp, HS., & Graham, DK. Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology. Journal of Medicinal Chemistry. (2019); 141(39): 15700-15709. Cited in PubMed; PMID: 31497954.
McDaniel, N.K., & Cummings, T.K., & Iida, M., & Hulse, J., & Pearson, H.E., & Vasileiadi, E., & Parker, R.E., & Orbuch, R.A., & Ondracek, O.J., & Welke, N.B., & Kang, G.H., & Davies, K.D., & Wang, X., & DeRyckere, D., & Graham D.K., & Wheeler D.K. MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Molecular Cancer Therapeutics. (2018); 17(11): 2297-2308. Cited in PubMed; PMID: 30093568.
Smart, S.K., & Vasileiadi, E., & Wang, X., & DeRyckere, D., & Graham, DK. The Emerging Role of TYRO3 as a Therapeutic Target in Cancer. Cancers (Basel). (2018); 10(12): 474.Cited in PubMed; PMID: 30501104.
Zhao, J., & Zhang, D., & zhang, w., & Stashko, M., & DeRyckere, D., & Vasileiadi, E., & Parker, R., & Hunter, D., & Liu, Q., & Zhang, Y., & Norris-Drouin, J., & Drewry, D., & Kireev, D., & Graham, D., & Earp, H., & Frye, S.V., & Wang, X. Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry.(2018); 61(22): 10242-10254. Cited in PubMed; PMID: 30347155.
Maldonado, JE., & Vasileiadi, E., & Mehta, S., & Sitt, H. (2021, April). Single Growth Curve for Newborn Weight Classification at Birth in the Nursery. Poster presented at: 2021 Downstate Research Colloquium; Brooklyn, NY.
Minson, KA., & Vasileiadi, E., & Madeline, GH., & Wang, X., & Frye, SV., & Earp, HS., & DeRyckere, D., & Graham, DK. (2019, March). Stromal cell activation of MAPK signaling pathways mediates resistance to MERTK inhibition in acute myeloid leukemia. Post er presented at: Proceedings of the American Association for Cancer Research Annual Meeting 2019; Atlanta, GA.
Summers, RJ., & Minson, KA., & Vasileiadi, E., & Wang, Xiadong., & Frye, SV., & Earp, HS., & DeRyckere, D., & Graham, DK. (2019, March). MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia. Poster presented at: Proceedings of the American Association for Cancer Research Annual Meeting ; Atlanta, GA.
Athens Medical Association
American Academy of Pediatrics
American Medical Association